Exclusive Summary

• Holds both US-FDA and UK-MHRA GMP certifications and is already registered in the US, enabling fast-track regulatory reliance and immediate commercial distribution globally.
• Offers a complete ER portfolio (25mg to 300mg), perfectly aligning with strict clinical titration protocols to avoid SJS, backed by a high-barrier extended-release formulation.
• Targets a massive demographic of ~50 million epilepsy and ~40 million bipolar disorder patients globally, serving as a first-line, guideline-recommended maintenance therapy.
• Leverages China's cost-efficient manufacturing capabilities through a ready-to-go Distribution model, ensuring high profit margins and supply chain stability for overseas partners.